CFO William A. Heyburn reported three transactions in Blade Air Mobility (BLDE) stock. On 08/01/2025 he received 139,286 Class A shares after the Compensation Committee certified that 2024 performance targets tied to previously granted PSUs had been achieved. To satisfy related tax obligations, the company withheld 76,177 shares at $3.99.
Following the vesting, Heyburn beneficially owned 1,463,940 shares. On 08/04/2025, acting under a pre-arranged Rule 10b5-1 plan dated 11/25/2024, he sold 46,918 shares at a weighted-average price of $4.94-$4.96, trimming his stake to 1,340,845 shares. The sale represents roughly 3 % of his current holdings and generated about $232k in gross proceeds. Net of all reported moves, Heyburn’s ownership increased by approximately 16 k shares, or +1 %.
No options or other derivative securities were transacted, and no additional insider participants were listed. Overall, the filing reflects routine equity compensation vesting combined with a modest, pre-scheduled liquidity sale, leaving the CFO with a substantial position aligned with shareholders.
Blade Air Mobility (NASDAQ: BLDE) Q2 2025 10-Q highlights
- Revenue rose 4% YoY to $70.8 m; Medical segment up 18% to $45.1 m, offsetting a 13% Passenger decline to $25.7 m.
- Cost discipline: Total operating expenses fell 5% to $75.8 m, driven by a 20% reduction in G&A and 32% lower selling & marketing spend.
- Profitability improving: Operating loss narrowed to $(5.0) m from $(12.1) m; net loss trimmed to $(3.7) m (-$0.05/sh) versus $(11.3) m (-$0.15/sh) prior-year.
- Segment Adjusted EBITDA grew 34% to $8.4 m; Medical contributed $6.0 m.
- Liquidity: Cash & equivalents $58.8 m plus $54.7 m short-term Treasuries; operating cash burn cut to $3.3 m (vs $7.1 m).
- Balance sheet: Warrant liability marked down to $3.0 m (from $5.8 m); goodwill now $44.3 m after organ-transport acquisitions.
- Share count: 81.7 m shares outstanding, up 2.3 m YTD due to equity compensation; stock-based comp $9.6 m YTD.
- Subsequent event: 1 Aug 25 agreement to sell Passenger business to Joby Aviation for up to $125 m ($90 m at close, $35 m earn-out, cash or JOBY stock). Transaction expected to be treated as discontinued operations.
- Guidance: none provided; management notes seasonality with stronger Q2–Q3 passenger demand.
Key takeaways: Blade is pivoting toward its higher-margin Medical segment while monetizing the Passenger operation. Liquidity remains solid and losses are shrinking, but execution risk on the Joby deal and continued passenger softness warrant monitoring.